{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Inflammatory bowel diseases", "dietary supplement", "herbal medicine", "oxidative stress", "prevention"]], "OtherID": [], "CitationSubset": ["IM"], "InvestigatorList": [], "SpaceFlightMission": [], "GeneralNote": [], "OtherAbstract": [], "PMID": "26799847", "DateCompleted": {"Year": "2017", "Month": "04", "Day": "17"}, "DateRevised": {"Year": "2022", "Month": "03", "Day": "31"}, "Article": {"ArticleDate": [{"Year": "2016", "Month": "02", "Day": "20"}], "ELocationID": ["10.1586/17474124.2016.1145546"], "Language": ["eng"], "Journal": {"ISSN": "1747-4132", "JournalIssue": {"Volume": "10", "Issue": "6", "PubDate": {"Year": "2016", "Month": "Jun"}}, "Title": "Expert review of gastroenterology & hepatology", "ISOAbbreviation": "Expert Rev Gastroenterol Hepatol"}, "ArticleTitle": "A mechanistic review on plant-derived natural compounds as dietary supplements for prevention of inflammatory bowel disease.", "Pagination": {"StartPage": "745", "EndPage": "758", "MedlinePgn": "745-58"}, "Abstract": {"AbstractText": ["Inflammatory bowel disease (IBD) is a recurrent idiopathic inflammatory condition, characterized by disruption of the gut mucosal barrier. This mechanistic review aims to highlight the significance of plant-derived natural compounds as dietary supplements, which can be used in addition to restricted conventional options for the prevention of IBD and induction of remission. Various clinical trials confirmed the effectiveness and tolerability of natural supplements in patients with IBD. Mounting evidence suggests that these natural compounds perform their protective and therapeutic effect on IBD through numerous molecular mechanisms, including anti-inflammatory and immunoregulatory, anti-oxidative stress, modulation of intracellular signaling transduction pathways, as well as improving gut microbiota. In conclusion, natural products can be considered as dietary supplements with therapeutic potential for IBD, provided that their safety and efficacy is confirmed in future well-designed clinical trials with adequate sample size."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "a Pharmaceutical Sciences Research Center , Kermanshah University of Medical Sciences , Kermanshah , Iran."}, {"Identifier": [], "Affiliation": "b Medical Biology Research Center , Kermanshah University of Medical Sciences , Kermanshah , Iran."}], "LastName": "Farzaei", "ForeName": "Mohammad Hosein", "Initials": "MH"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "c Faculty of Pharmacy , Tehran University of Medical Sciences , Tehran , Iran."}], "LastName": "Bahramsoltani", "ForeName": "Roodabeh", "Initials": "R"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "d Medicinal Plants Research Center , Institute of Medicinal Plants, ACECR , Karaj , Iran."}, {"Identifier": [], "Affiliation": "e International Campus ICTUMS , Tehran University of Medical Sciences , Tehran , Iran."}], "LastName": "Abdolghaffari", "ForeName": "Amir Hossein", "Initials": "AH"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "f Young Researchers and Elite Club, Karaj Branch , Islamic Azad University , Karaj , Iran."}], "LastName": "Sodagari", "ForeName": "Hamid Reza", "Initials": "HR"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "g Department of Radiology , Massachusetts General Hospital, Harvard Medical School , Boston , MA , USA."}], "LastName": "Esfahani", "ForeName": "Shadi A", "Initials": "SA"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "h Research Center for Immunodeficiencies, Children's Medical Center , Tehran University of Medical Sciences , Tehran , Iran."}, {"Identifier": [], "Affiliation": "i Department of Immunology, School of Medicine , Tehran University of Medical Sciences , Tehran , Iran."}, {"Identifier": [], "Affiliation": "j Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA) , Universal Scientific Education and Research Network (USERN) , Tehran , Iran."}], "LastName": "Rezaei", "ForeName": "Nima", "Initials": "N"}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "England", "MedlineTA": "Expert Rev Gastroenterol Hepatol", "NlmUniqueID": "101278199", "ISSNLinking": "1747-4124"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Anti-Inflammatory Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Gastrointestinal Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Phytochemicals"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["adverse effects", "therapeutic use"], "DescriptorName": "Anti-Inflammatory Agents"}, {"QualifierName": ["adverse effects"], "DescriptorName": "Dietary Supplements"}, {"QualifierName": ["adverse effects", "therapeutic use"], "DescriptorName": "Gastrointestinal Agents"}, {"QualifierName": ["drug effects"], "DescriptorName": "Gastrointestinal Microbiome"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["diagnosis", "immunology", "microbiology", "prevention & control"], "DescriptorName": "Inflammatory Bowel Diseases"}, {"QualifierName": ["drug effects", "immunology", "microbiology"], "DescriptorName": "Intestines"}, {"QualifierName": ["adverse effects", "therapeutic use"], "DescriptorName": "Phytochemicals"}, {"QualifierName": [], "DescriptorName": "Protective Factors"}, {"QualifierName": [], "DescriptorName": "Risk Factors"}, {"QualifierName": [], "DescriptorName": "Treatment Outcome"}]}, "PubmedData": {"ReferenceList": [], "History": [{"Year": "2016", "Month": "1", "Day": "23", "Hour": "6", "Minute": "0"}, {"Year": "2016", "Month": "1", "Day": "23", "Hour": "6", "Minute": "0"}, {"Year": "2017", "Month": "4", "Day": "18", "Hour": "6", "Minute": "0"}], "PublicationStatus": "ppublish", "ArticleIdList": ["26799847", "10.1586/17474124.2016.1145546"]}}], "PubmedBookArticle": []}